ArticleTranslational psychiatry2025
Remote monitoring of wide-ranging real-world changes in adults following ADHD medication initiation.
Article in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While attention-deficit/hyperactivity disorder (ADHD) medication is effective for core symptoms, its broader and progressive impacts remain underexplored. This study evaluated real-world changes in ADHD symptoms and impairments, co-occurring psychiatric symptoms, physical measures, and health behaviors following ADHD medication initiation in adults. Data were drawn from a remote monitoring cohort recruited from adult ADHD clinic waiting lists in the United Kingdom and Spain. Participants completed 4-weekly smartphone-based self-reports and continuously wore a wearable device to monitor behaviors such as physical activity and sleep. We additionally developed novel wearable-derived features to approximate restlessness. A subset of 176 participants with valid baseline (off-medication) and up to three 4-weekly on-medication assessments was included. Compared to the off-medication phase, the on-medication phase was significantly associated with improvements in ADHD symptoms and impairments, as well as reductions in depression, anxiety, irritability, and aggression. Additional changes included reduced alcohol use, healthier diet, elevated heart rate, lower blood pressure, reduced waist circumference, increased physical activity, less restlessness, and improved sleep quality. Several domains showed significant progressive changes, including continued improvements in ADHD symptoms, impairments, and irritability; rising heart rate; declining body weight; and delayed sleep timing. These findings suggest ADHD medication in adults is associated with broad real-world benefits alongside some potential concerns, such as elevated heart rate and delayed sleep. This study highlights the potential of remote monitoring technologies to capture multidimensional treatment responses in daily life and provides a foundation for future research to support both clinical care and self-management in ADHD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.